Introduction
The measurement of the bone mineral content of the skeleton has revolutionized the study of osteoporosis in the last 25 years. The development of sophisticated techniques of bone mass assessment was stimulated by the recognition that 30% of bone must be lost before a radiological diagnosis of osteoporosis can be made"2. Initially methods of grading the degree of bone loss from simple radiographs of the lumbar spine3 and the femoral neck4 were described. The poor precision of these techniques' led to the measurement of the thickness of cortical bones as an estimate of bone mass. The Barnett/Nordin index3 was introduced to measure a single metacarpal, but it was followed by a rash of methods for other appendicular bones6 -8. The precision of the metacarpal method was improved by increasing the number of metacarpals measured from a single bone to three9 or six'0"'. The need to measure clinically more important trabecular bone was initially tackled in the early 1960s when Cameron and Sorenson'2 described the first method for measuring bone mass by the absorption of monoenergetic photons. The distal third of the radius became the most widely used site'3 but methods have also been reported for the os calcis'4, the femur"5 and the metacarpal16. All these sites, while containing trabecular bone, consist primarily of cortical bone. Measurement of the radial metaphysis increased the proportion of trabecular bone measured'7, but it then became possible to examine the bones of the spine using a dual isotope technique of photon absorptiometry'8. Either a single dichromatic source'9 or two monochromatic sources20 are used to measure the 2nd, 3rd and 4th lumbar vertebrae, allowing an estimate of axial trabecular bone to be made21. Recently the use of CT scanners has allowed complete separation of trabecular and cortical bone in the vertebrae22.
There are only two methods described for measurement of total bone mass. Two groups of workers have reported their method for adapting dual photon absorptiometry to measure total body bone mineral content (TBBM)23'24. The method is fairly reproducible, with precision varying from 1.8%24 to a long-term figure of 3.0%23. It has a major advantage in using only tiny radiation doses, but it is only available in a very few centres at the present time. Total bone mass measured by total body calcium (TBCa) is potentially more widely available and correlates extremely well with TBBM25. This paper reviews the development of the TBCa technique, describes the method of measurement and reports some examples ofits clinical use particularly as experienced bymy colleagues and I in Edinburgh.
Basic principles of total body calcium measurement Measurement of TBCa is carried out by in-vivo neutron activation analysis (NAA), the development of which has opened an era of research into the elemental composition of human subjects26. NAA of calcium depends on the interaction of neutrons with calcium-48, a stable isotope accounting for 0.18% of the element27. An unstable isotope, calcium49, is produced and this decays with a half-life of 8.8 minutes28 to scandium-49. During the reaction gamma rays are emitted, the principal energy of which is 3.1 mega-electron volts29. The rays so produced are measured in a whole-body counter and, by comparison with a phantom containing a known quantity of calcium, a figure for total body calcium in grams is produced. Some groups, including our own, 'correct' the final count to allow for the influence of body habitus on activation and counting efficiency. The technique cannot distinguish between intra-and extraosseous calcium deposits but, as bones contain 99% of the body's calcium content30, it is a reasonable assumption that TBCa is a measurement of total bone mass.
Methods of measurement of partial body bone mass have been reported for the hands3', forearm32, lumbar spine33'34 and torso35. Few of these methods survive today because of their relatively poor precision36
The use of total body NAA to measure TBCa was first described in 196837. The neutron source employed varies from multiple plutonium-beryllium sources38, to single39 or dual40 neutron generators.
However most groups, including our own, rely on a cyclotron4'-. Use of the technique is limited not only by the availability of a neutron source and a sensitive whole-body counter, but also because of the precision and radiation dose involved in repeated measurements. weight, age, menopausal status and sex of the subjects. TBCa has been found to be strongly dependent on height45"47"48 and span'5 in both sexes, although males have an average of 20% more calcium than females of the same height48. Weight has also been found to be related to TBCa by some groups45"47, but this effect disappears if weight is included in the measurement corrections alluded to above45 and is anyway not an invariable finding48. A correlation has also been found between TBCa and muscle mass as measured by total body potassium49. In all published studies TBCa is dependent on menopausal status45 or age in women over 5547. 48 . However, only one group has found any relationship between age and TBCa in males, or in females under the age of 5547. Using the correlations described, most groups of workers have reported formulae for predicting TBCa in an individual derived from multiple regression equations45"47"48. Expressing the measured TBCa as a percentage of that predicted allows normalization of the data, reducing the coefficient of variation to 6.2-9.0% in men and 6.6-12.0% in women4'5"7"
Details of measurement procedure used in Edinburgh The method has been fully published elsewhere'5. In summary, neutrons produced by the Medical Research Council cyclotron were directed at a patient standing in a rigid 3 cm thick polyethylene kiosk mounted on a turntable which was sited 5.4 metres from the source. The back wall of the kiosk was movable and was adjusted so that the subject's trunk was in contact with both front and back walls. The fixed neutron dose was delivered to the posterior surface of the body for 22 seconds and then, after rotation through 1800, the same dose was delivered to the anterior surface. The radiation dose to the whole body was calculated at 13.2 mSv. After irradiation, the patient was transferred to a shadow-shield whole-body counter containing four 15 x 10 cm sodium iodide crystals, two above and two below the bed. Four 200 cm scans, each lasting 5 minutes, were then performed at constant speed. The patient spectrum covering the energy range 0-4 MeV was recorded on a multi-channel analyser. A twenty-minute background count, measured using an inactive phantom, was then subtracted from the patient spectrum and the difference punched on computer tape for analysis. The smoothed subject spectra in the energy range 1.0-3.4 MeV were then compared with those obtained from an anthropomorphic phantom containing a known quantity of calcium nitrate using the least squares technique . Corrections were made for radioactive decay by measuring the activation time and the delay before measurement. Allowances were made for the influence of body habitus on the activation and counting efficiency using the subject's height, body build, subcutaneous fat and the distance between the patient and the walls of the activation chamber. This calculation produced an expression for TBCa in grams.
My co-workers have used the above technique to measure TBCa for 20 normal controls of both sexes. There was a large variation in the TBCa results for both groups. The female results ranged from 596, to 1036 grams with a mean of 821 grams + 15.2% (coefficient of variation), while the males ranged from 886-1428 grams with a mean of 1143 grams + 11.7%45. Using multiple regression analysis, the TBCa was found to be strongly dependent on arm span and menopausal status (years post-menopause) in females. Using these relationships, normalization reduced the coefficient of variation of TBCa in controls to 7.8% in males and 6.5% in females. From the slope of the regression line, the mean menopausal loss was calculated as 1.5% per annum in Edinburgh45, a figure slightly greater than the 1.1% in New York reported by Cohn et al. 47 , although they assumed a uniform menopause at age 55.
The reproducibility of the technique was investigated by repeatedly measuring the calcium content of a phantom consisting of a human skeleton encapsulated in tissue-equivalent rubber. The reproducibility expressed as the coefficient of variation of 10 repeated measurements was 1.8%45. Recently we have derived a figure for in vivo precision from the deviatiohs of individual measurements from a line of regression representing the change in TBCa over an 18-month period in a large group of patients with rheumatic diseases. The mean standard deviation for all patients was calculated as an estimate of in vivo precision and a final figure of 2.9% produced46.
The above method, including the normalization procedure, is necessary for cross-sectional analysis of TBCa. However, longitudinal analysis does not require normalization as subjects act as their own controls. In our hands the change of TBCa over a period of 18 months was calculated by 3 or 4 measurements of TBCa in grams. A linear regression line was drawn representing the change of TBCa with time, and from the slope of the line the rate of change was calculated and expressed as a percentage of the individual's initial value. To date no group has reported the rate of change of TBCa in normals, perhaps because of the fairly high radiation dose.
Clinical relevance of total body calcium measurements
TBCa has been used to study patients with osteoporotic compression fractures in three centres. There were significant reductions in the mean total body calcium of women patients compared with controls by 16%5o.51 to 18%5', but there was a wide overlap which amounted to 55% of the patient group in one study53. The technique has been used to study cross-sectional bone mass in a variety of clinical situations including different racial groups54, Paget's disease"5, chronic renal disease56 57, thyroid disorders5", parathyroid dysfunction59 and acromegaly60. The results of many of these studies have recently been reviewed26.
In Edinburgh my work and that of my co-workers has considered TBCa in various rheumatic diseases and bronchial asthma as well as considering the possible seasonal variation of TBCa61. Total bone mass was found to be normal in primary generalized osteoarthrosis (PGOA)62 and, in the absence of longitudinal data from normal controls, this group of patients has been used for assessment of ageassociated bone loss. In rheumatoid arthritis (RA) TBCa was found to be significantly reduced by 5.3% in male and 6.8% in female patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs) alone, and further reduced by 11.5% in male and 15.5% in female patients receiving additional corticosteroids in a mean dose of 6.1-6.3 mg/day63. The more substantial bone loss in the corticosteroidtreated patients was considered to be related to the additional therapy rather than the disease process, and subsequently as little as 5 mg of prednisolone/day was found to be associated with significant reduction of TBCa compared to that predicted64. TBCa in patients treated with corticosteroids for at least one year was found to be strongly correlated with the mean daily dose of prednisolone administered, but not with the duration of therapy or the total dose of prednisolone received. This relationship suggested that the loss of bone mass associated with corticosteroid therapy occurred early in the course of the treatment63. The corticosteroid-induced bone loss of RA was found to be significantly greater than that of patients with bronchial asthma or polymyalgia rheumatica when matched for daily dose of prednisolone64'65, and indeed these preliminary studies failed to show any significant reduction in bone mass in the latter two diseases despite mean daily doses of 7.5-7.7mg of prednisolone/day.
Longitudinal studies utilizing TBCa may have more value than cross-sectional work as the problems of normalization are omitted. Previous reports using TBCa have highlighted the value of treatment of established postmenopausal osteoporosis with calcitonin66 -68 and the anabolic steroids meth-androstenolone69 and stanozalol68'70, although treatment with methandrostenolone has not always been associated with an increase in TBCa7 .
Longitudinal assessment of bone mass in patients with RA has given support to the hypothesis of corticosteroid-induced bone loss occurring early in the course of therapy. In patients established on corticosteroids, no further mean loss of calcium occurred over a period of 18 months, while there was a mean loss of 3.4% per annum in those patients receiving NSAIDs alone65'72. The annual rate of bone loss in the 'control' patients with PGOA was 1.6% per annum72, which may well represent menopausal loss as the figure is very similar to the figure of 1.5% reported in cross-sectional studies by my colleagues45. Clinical response to antirheumatic drugs (gold and penicillamine) and prophylactic oral calcium supplements used in patients with RA did not reduce the rate of bone loss over a period of 18 months72.
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